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Like all herpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV) can produce either latent or lytic infection. The latent v-FLIP gene is
a strong activator of NFκB, and in primary effusion lymphoma (PEL) cells, blockade of NFκB activation is associated with enhanced lytic gene
expression, while overexpression of p65 impairs expression of reporter genes driven by lytic promoters. This has led to the suggestion that NFκB
activation may promote latency by suppressing lytic reactivation. Here we examine in detail the effects of NFκB activation on KSHV replication
in several cell types. In accord with earlier work, we find that inhibition of NFκB signaling in PEL cells is associated with enhanced lytic
reactivation of KSHV. Similarly, in de novo KSHV infection of primary endothelial cells, inhibition of NFκB signaling leads to an increase in lytic
gene expression and enhanced virion production. By contrast, KSHV-infected human foreskin fibroblasts (HFF) show no increase in spontaneous
lytic reactivation when NFκB is inhibited. Moreover, if NFκB activation is always inhibitory to lytic gene expression, one might expect its
activation to be suppressed during the lytic cycle. However, we find that NFκB signaling is strongly and consistently activated in lytically infected
cells of all lineages. Together these data indicate that (i) the relationship of NFκB activation to latency and lytic reactivation is not uniform, but is
dependent on the cellular context; and (ii) even though NFκB activation is inhibitory to lytic gene expression in some contexts, such inhibition is
at least partially bypassed or overridden during lytic growth.
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Kaposi's sarcoma-associated herpesvirus (KSHV, also
called human herpesvirus 8) is the etiologic agent of Kaposi's
sarcoma (KS), an inflammatory and proliferative lesion
affecting the microvascular endothelium. KSHV also targets
B lymphocytes, and is linked to two rare lymphoproliferative
syndromes, multicentric Castleman's disease (MCD) and
primary effusion lymphoma (PEL) (Arvanitakis et al., 1996;
Moore and Chang, 1998; Soulier et al., 1995). Like all
herpesviruses, KSHV can execute two different genetic
programs, known as latency and lytic growth. In latency,⁎ Corresponding author. Fax: +1 415 476 0939.
E-mail address: ganem@cgl.ucsf.edu (D. Ganem).
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doi:10.1016/j.virol.2007.12.044viral gene expression is strongly restricted, with only a handful
of the virus' nearly 100 genes being expressed. The latent viral
genome is maintained as a circular nuclear plasmid, and no
viral progeny are produced. Latency is usually the default
pathway following experimental infection in cultured cells
(Vieira et al., 2001; Bechtel et al., 2003). However, if latently
infected cells are exposed to certain stimuli (such as: phorbol
esters or HDAC inhibitors) latency can be disrupted and lytic
replication triggered. The lytic program proceeds via a
temporally regulated cascade of gene expression, in which
lytic cycle-specific genes are activated in at least 3 classes:
immediate-early (IE), delayed-early (DE) and late (L). Viral
DNA replication follows DE gene expression, and progeny
genomes are encapsidated into virions and released.
KS tumors are primarily latently infected, but a small number
of cells in the lesion are lytically infected (Staskus et al., 1997),
Fig. 1. Inhibition of NFκB in BCBL-1 cells leads to increased lytic gene
expression as well as increased apoptosis. BCBL-1 cells were treated with the
indicated amounts of Bay 11-7082 or vehicle (DMSO) for 30 min at 37 °C. Cells
were resuspended in fresh media and total RNA and total protein were harvested
at 48 h post treatment. Taqman real time PCR was performed on cDNA made
from total RNA. ddCT values (log based 2 indicator of fold change) for lytic
genes Orf 50, Orf57 and gB are shown in panel (A). All values were normalized
to GAPDH levels, and are expressed for each gene in BCBL-1 cells treated with
Bay 11-7082 relative to those treated with the same amount of DMSO. Panel (B)
shows a dose dependent increase in apoptosis as measured by PARP cleavage
with increasing doses of the Bay 11-7082 compound. 20 μg of total protein was
blotted for PARP protein and β actin as a loading control.
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play important roles in KS pathogenesis (Ganem, 2006). A
single viral gene, RTA (Replication and Transcription Activa-
tor) controls this genetic switch; forced expression of RTA in
latency triggers lytic reactivation, and mutational inactivation of
RTA blocks lytic reactivation (Sun et al., 1998; Lukac et al.,
1999). However, little is known of the physiologic stimuli that
activate RTA expression to trigger lytic growth, and still less is
known about how latency, once established, is stably main-
tained (that is to say, how the expression of RTA and other lytic
genes is prevented).
Several years ago, Brown et al. (2003) demonstrated that
treatment of PEL cells with Bay 11-7082, a known pharmaco-
logical inhibitor of NFκB activation, triggered enhanced spon-
taneous lytic reactivation. Because KSHV latency is associated
with expression of the v-FLIP gene, which tonically activates
NFκB by binding to NEMO and activating IKK (Field et al.,
2003; Liu et al., 2002), latently infected cells have elevated
NFκB activity. A model has accordingly been proposed that
NFκB activation opposes lytic reactivation; in support of this
notion, Brown et al. (2003) reported that overexpression of p65
inhibits expression of luciferase reporter genes driven by several
KSHV lytic promoters. Here we have examined the role of
NFκB in lytic reactivation in several cell types other than PEL
cells (which have been selected for stable latency in vivo and
display a strong dependence on v-FLIP-mediated NFκB
activation (Guasparri et al., 2004)). We find that the dependence
of latency on NFκB activation is variable and dependent upon
the cellular context— primary endothelial cells behave similarly
to PEL cells, but equally permissive human fibroblasts show no
enhancement of lytic reactivation when the NFκB activation
pathway is inhibited. Moreover, NFκB is strongly activated
during lytic replication in all cell types, indicating that if there is
a block to lytic gene expression mediated by p65 it must be at
least partially bypassed or overcome in the context of the lytic
program.
Results
Inhibition of NFκB in PEL cells leads to increased lytic gene
expression and apoptosis
Although Brown et al. (2003) reported that NFκB inhibition
upregulated lytic gene expression, other investigators have not
observed lytic derepression in this setting (Keller et al., 2000).
We therefore re-examined this issue. In accord with previous
work (Brown et al., 2003), we found that inhibition of NFκB
signaling in KSHV positive PEL cells leads to increased expres-
sion of an array of lytic genes. BCBL-1 cells, a line persistently
infected with KSHV, were treated with a range of doses (1, 2, 4,
6 μM) of the compound Bay 11-7082 (in DMSO), an irreversible
inhibitor of IκBα phosphorylation, or a corresponding amount
of DMSO. Total RNAwas isolated from the cells and expression
of several lytic genes was assayed by Taqman real time RT-PCR.
As shown in Fig. 1A, cells treated with Bay showed a marked
increase in expression of an immediate-early lytic gene (ORF
50), a delayed-early gene (ORF 57) and a late lytic gene (gB).This increase was seen at all assayed doses and followed a dose-
dependent trend.
NFκB inhibition in PEL cells has been reported to be
associated with increased apoptosis of the PEL cells (Keller
et al., 2006, 2000). Accordingly, we examined apoptosis levels
by immunoblotting for PARP, a downstream cleavage target
of caspases 3 and 7 in the apoptotic cascade (Fig. 1B). As
expected, increased cleavage of PARP was seen in BCBL-1
cells treated with Bay 11-7082 (lanes 1,3,5,7) but not the
corresponding vehicle, DMSO (lanes 2,4,6,8). Because apop-
tosis was assayed in the mass culture rather than at the single
cell level, we do not know if the cell population experiencing
lytic reactivation was the same or different from that undergoing
apoptosis.
de novo KSHV infection of endothelial cells in the context of
NFκB inhibition leads to increased cytotoxicity, lytic reactivation
and apoptosis
Previous experiments investigating the link between the
NFκB signaling pathway and the KSHV latent-lytic switch have
been done almost exclusively in PEL lines (Brown et al., 2003;
Guasparri et al., 2004; Keller et al., 2006, 2000; Sgarbanti et al.,
2004). But PEL cells are very far removed from the initial latent
infection, having been selected in vivo for stable episome
maintenance despite rapid growth— a selection that we know
requires epigenetic changes that are likely not present in KS-
derived endothelial (spindle) cells or most latently infected cells
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PEL cells may not be fully representative of all cells in which
latent KSHV infection can be observed. Accordingly, we have
examined several other cell types in which de novo KSHV
infection can produce latency, and which are permissive for
lytic reactivation. These include primary human umbilical vein
endothelial cells (HUVEC) and secondary human foreskin
fibroblasts (HFF).
To examine the role of NFκB in HUVEC cells, we generated
a HUVEC culture stably expressing a degradation-resistant
mutant of IκBα. This version of IκBα (IκB super-repressor,
IκBSR) contains two Ser/Ala mutations at positions 32 and 36,
rendering it resistant to phosphorylation by the IκBα kinase
(IKK) and therefore refractory to subsequent degradation by the
proteasome. This results in a stabilization of IκBα-NFκB
complexes in the cytoplasm of the cell, inhibiting the ability of
the NFκB transcription factor to translocate into the nucleus. As
previously described (Grossmann et al., 2006), HUVECs were
transduced with retrovirus encoding IκBSR and selected for a
short time with puromycin. These cells were assayed for inhi-
bition of NFκB signaling by treatment with TNFα (10 ng/ml)
for 2 h, isolation of nuclear extracts, followed by electro-
mobility shift assay (EMSA) to determine NFκB DNA binding
activity. Fig. 2A shows complete inhibition of inducible NFκB
DNA binding in IκBSR HUVECs upon treatment with TNFα,
in contrast to those expressing the empty vector, which display
strong NFκB induction.
Next, IκBSR and control HUVECswere infected with KSHV
at levels that were previously determined to give 100% LANA
positive cells and low (b1%) spontaneous lytic reactivation;
infected and mock-infected cells were then followed for 3 days.
Fig. 2B shows representative pictures of the mock- or KSHV-
infected HUVEC monolayers at 66 h post infection. Upon
KSHV infection, IκBSR expressing cells showed reproducible
increases in cytotoxicity as compared to control cells. In some
cases, this toxicity was visible at time points as early as 18 h post
infection (data not shown), but was most pronounced at the 66 h
time point.
To determine whether the observed increases in cell toxicity
correlated with increased spontaneous lytic reactivation of the
virus, IκBSR and control HUVECs previously infected with
KSHVwere fixed and stained for the delayed-early protein ORF
59 (Fig. 2C). The lower panel of Fig. 2C shows representative
fluorescence images of cells stained for ORF 59 expression (red)
and DAPI (blue) at 66 h post infection (hpi). As is evident in the
picture, and is quantified in the histogram in the upper panel,
IκBSR HUVECs showed a significant increase in ORF 59
positive cells. In order to better quantify the increase in lytic gene
expression in IκBSR HUVECs, total RNA was harvested from
cells at 66 hpi. Real time quantitative RT-PCR was performed to
determine the relative abundance of mRNAs that spanned the
multiple phases of temporal regulation of the lytic cycle. As is
shown in the upper panel of Fig. 2D, all three lytic genes assayed
(ORF50, ORF57 and gB) showed increased expression in
IκBSR HUVECs over control cells. Values are normalized to
levels of the endogenous GAPDH gene for each sample, and are
displayed as ddCT values (log base 2) showing the relativeincrease in expression of the genes in IκBSR HUVECs over
control cells.
To determine whether the observed increase in lytic gene
expression in the IκBSR HUVECs corresponded to an in-
creased production of KSHV virions, supernatants from
infected cells were collected at 42 and 66 hpi. Supernatants
were cleared of dead cells and cellular debris and the remaining
virions were concentrated by centrifugation. Exogenous DNA
was removed by DNase digestion; following inactivation of the
nuclease, virions were lysed and virion DNA was extracted as
described in the Materials and methods section. Real time
quantitative Taqman PCR was performed on the isolated virion
DNA, and the abundance of viral genomes was quantified by
measuring the relative levels of the PAN promoter sequence
(Fig. 2D, lower panel), normalized to a spiked-in control.
IκBSR HUVECs showed increased production and release of
virions into the supernatant at both the 42 and 66 hpi time
points, reaching a maximum of 8-fold. In conjunction with the
observed increases in staining for lytic protein and lytic gene
expression, the increased production of KSHV virions supports
the view that inhibition of the NFκB pathway in primary human
endothelial cells leads to increased spontaneous lytic reactiva-
tion of KSHV upon de novo infection.
Although much of the cytotoxicity observed in the infected
IκB-SR HUVECS could be attributed to cell necrosis from lytic
infection, we also asked whether there was an increase in apo-
ptosis in this setting. Lysates taken at 66 hpi were blotted with an
anti-PARP antibody to assess the extent of PARP cleavage in the
individual cultures (Fig. 2E). Increased PARP cleavage was
observed in the KSHV-infected IκBSR HUVECs (lane 4) as
compared to the infected control cells (lane 2), suggesting en-
hanced levels of apoptosis in these cells. This is not entirely
surprising, as many lytic herpesviral gene products can trigger
apoptosis. Additionally, since NFκB is known to upregulate an
anti-apoptotic cascade in endothelial cells (Stehlik et al., 1998),
inhibition of this pathway in infected cells might be expected to
trigger enhanced apoptosis.
KSHV-infected human fibroblasts do not display enhanced lytic
replication or cytotoxicity in the presence of NFκB inhibition
To determine whether the cell death associated with KSHV
infection in the context of NFκB inhibition is common to all cell
types, human foreskin fibroblasts (HFF) expressing the IκBSR
were constructed. HFFs have been previously shown to be fully
permissive for both latent and lytic KSHV infection (Bechtel
et al., 2003; Vieira and O'Hearn, 2004). As expected, IκBSR
HFFs display strong inhibition of NFκB signaling in response to
TNFα (Fig. 3A), relative to control HFFs transduced with an
empty retroviral vector. These cells were then infected with
KSHV under conditions promoting latent infection of nearly all
cells. Despite robust latent infection, as evaluated by staining for
LANA (green, Fig. 3C), no increase in cell death (Fig. 3B) or
ORF 59 staining (red, Fig. 3C) was detected in IκBSR HFFs
as compared to control cells. Likewise, no increase in lytic
mRNA expression or virion production was observed in these
cells (Fig. 3D). (In fact, for unclear reasons the levels of lytic
Fig. 2. Inhibition of NFκB in HUVEC cells leads to increased cellular toxicity, increased lytic gene expression, virion production and apoptosis upon de novo infection
with KSHV. (A) HUVECs were transduced with retroviruses encoding a degradation-resistant mutant of IκBα (IκBSR). NFκBDNA binding activity in these cells was
blocked upon treatment with 10 ng/ml TNFα for 2 h, as compared to those expressing vector alone. (B) HUVECs expressing IκBSR show increased cellular toxicity
upon de novo latent KSHV infection. HUVECs expressing either vector or IκBSR were infected with KSHV for 6 h, pictures were taken at 66 h post infection.
(C) KSHV-infected IκBSR HUVECs show increased staining for ORF 59 (red) as compared to HUVECs expressing vector alone. Cells were fixed and stained at 66 h
post infection. (D) Taqman real time PCR ddCT values (log base 2) for ORF 50, ORF 57 and gB (upper panel) and PAN promoter values (lower panel) show increased
lytic gene expression and enhanced virion production in IκBSR expressing HUVECs. All values were normalized to GAPDH or spike-in DNA levels, and are
expressed for each gene in IκBSR HUVECs relative to vector HUVECs. (Please see Materials and methods section for details on virion DNA isolation.) (E) IκBSR
HUVECs show increased apoptosis upon infection with KSHV. Total protein was isolated from all cells (floating and adherent to the dish) from vector and IκBSR
HUVECs at 66 h post infection. 20 μg of total protein was blotted for PARP protein and β actin as a loading control.
97C. Grossmann, D. Ganem / Virology 375 (2008) 94–102transcripts modestly decreased in the presence of IκB-SR.) Thus,
neither lytic reactivation nor cell injury is an ineluctable con-
sequence of KSHV infection in the absence of NFκB activation.
Clearly, the relationship between NFκB signaling and sponta-
neous lytic reactivation is dependent on the cellular context.NFκB signaling is activated in lytically infected cells of all
lineages
Data showing that inhibition of NFκB induces lytic gene
expression in HUVEC and PEL cells suggest that NFκB
Fig. 3. Inhibition of NFκB in human foreskin fibroblasts (HFF) does not lead to increased cellular toxicity, increased lytic gene expression and virion production upon
de novo infection with KSHV. (A) HFFs were transduced with retrovirus encoding a degradation-resistant mutant of IκBα (IκBSR). NFκB DNA binding activity in
these cells was blocked upon treatment with 10 ng/ml TNFα for 2 h, as compared to those expressing vector alone. (B) HFFs expressing IκBSR show no increase in
cellular toxicity upon de novo latent KSHV infection. HFFs expressing either vector or IκBSR were infected with KSHV for 6 h, pictures were taken at 66 h post
infection. (C) No increase in ORF 59 staining was seen in IκBSR HFFs as compared to vector despite extensive latent KSHV infection as determined by staining for
LANA (green). Cells were fixed and stained at 66 h post infection. (D) Taqman real time PCR ddCT values for ORF 50, ORF 57 and gB (left panel) and PAN promoter
values (right panel) show no increase in lytic gene expression and or virion production in IκBSR expressing HFFs. All values were normalized to GAPDH or spike-in
DNA levels, and are expressed for each gene in IκBSR HFFs relative to vector HFFs.
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this, Brown et al. (2003) reported that overexpression of
recombinant p65 can extinguish gene expression from cotrans-
fected reporter genes driven by lytic KSHV promoters. These
data suggest that NFκB activationmay be incompatible with lytic
gene expression and lead to the prediction that the lytic cycle
might actively suppress NFκB activation. To test this prediction,
we examined the state of NFκB activity at several time points
during the progression of lytic KSHV infection. Contrary to the
predictions of this model, we found robust NFκB activation in
several cell types including HUVECs, HFFs and 293T. The
NFκB activation state of HUVECs and HFFs was examined
during both latent and lytic KSHVinfections. Cells were infected
with either KSHV alone or KSHV followed by an adenovirus
encoding the lytic transactivator RTA (AdRTA). At 48 hpi
nuclear extracts were prepared from the cells and NFκB DNA
bindingwas assessed by EMSA (Fig. 4A). IncreasedNFκBDNA
binding could be seen in HUVECs upon latent infection (upper
panel, lane 3) and was further enhanced upon reactivation with
AdRTA (upper panel, lane 4). HFFs showed similarly increased
NFκB DNA binding upon lytic KSHV infection (Fig. 4A, lower
panel). Moreover, this enhanced NFκB was functionally active,
as judged by its ability to upregulate expression of an NFκB-
dependent luciferase reporter. 293Tcells were cotransfected withplasmids encoding CD8, RTA, and an NFκB-luciferase reporter.
36 h post transfection, cells expressing CD8 (and therefore RTA)
were enriched for by binding to magnetic beads bearing anti-
CD8. The next day, these cells were either infected with KSHVor
mock-infected; at 48 h post infection, luciferase levels were
assayed (Fig. 3B). KSHV-infected, RTA-expressing cells showed
enhanced luciferase readings, indicating increased NFκB-
dependent transcriptional activation under these conditions.
(We note that the extent of upregulation of the reporter observed
here is surely an underestimate of the degree of NFκB activation,
owing to the global turnover of host mRNAs during lytic KSHV
replication (Glaunsinger and Ganem, 2004).)
As another indication of the activation state of the NFκB
pathway during lytic growth, we assayed for phosphorylation of
IκBα by the IKK complex in lytically infected HUVECs. Cells
were infected with either KSHV alone or KSHV plus AdRTA;
extracts were prepared at 48 and 72 hpi and assayed by
immunoblotting for phospho-IκBα and total levels of IκBα.
Fig. 4C shows increased phosphorylation of IκBα in lytically
infected cells by 48 hpi (top panel, lane 3, bottom band) and a
corresponding decrease in steady state levels of total IκBα protein
in these cells (middle panel, lane 3). By 72 hpi the intracellular
pool of IκBα is virtually totally depleted, most likely as a result of
proteasome action, and possibly exacerbated by KSHV-mediated
Fig. 4. NFκB signaling is activated in lytically infected cells. (A) Increased NFκB DNA binding activity is observed in lytically infected HUVECs (upper panel) and
HFFs (lower panel), as compared to both uninfected, and latently infected cells. Nuclear fractions were harvested at 48 h post infection, 5 μg of protein was used in
each binding reaction. (B) Increased NFκB transcription is shown in 293Tcells cotransfected with RTA and NFκB-luciferase reporter at 48 h post infection. Both mock
and KSHV cells were transfected with CD8, RTA and luciferase plasmids for 36 h before infection, and enriched for CD8, and therefore RTA positive cells, using anti-
CD8 coupled beads over magnetic columns. (C) Lytically infected HUVECs show increased phosphorylation of IκBα (top blot, lower band) and corresponding
decrease in levels of total IκBα (middle blot) demonstrating active NFκB signal transduction.
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(Glaunsinger andGanem, 2004). These data affirm that the NFκB
pathway is upregulated during lytic replication, and that this
induction is occurring at or above the level of IKK activation.
Discussion
Previous studies have described complicated interactions
between the NFκB signaling pathway and KSHV infection in
the context of PEL cell lines (Brown et al., 2003; Guasparri et al.,
2004; Keller et al., 2006, 2000; Sgarbanti et al., 2004). These
studies have shown increased lytic gene induction upon chemical
inhibition of NFκB (Brown et al., 2003), enhanced apoptosis upon
chemical inhibition of NFκB or knockdown of v-FLIP, a potent
NFκB inducer (Guasparri et al., 2004;Keller et al., 2006), and even
production of defective KSHV particles upon genetic inhibition of
NFκB in TPA-induced PEL cells (Sgarbanti et al., 2004).
Additionally, inhibition of RTA-mediated transactivation of lytic
gene promoters was shown in the context of overexpression of the
p65 subunit of NFκB (Brown et al., 2003). Taken together, these
accounts have led some to propose a model of suppression of lytic
gene expression and function by NFκB activation in PEL cells.
In our hands, inhibition of NFκB in BCBL-1 cells by treatment
with Bay 11-7082 led to increases in both lytic gene expression, in
agreement with the work of Brown et al. (2003), and enhanced
apoptosis, in accord with the observations of Guasparri et al.(2004). Results in HUVEC cells were largely congruent with these
PEL observations; however, KSHV-infected human fibroblasts
behaved completely differently — they displayed neither en-
hanced cytotoxicity nor increased spontaneous lytic gene
reactivation. These results led us to conclude that the relationship
between NFκB and spontaneous reactivation of KSHV is
complex, non-uniform and dependent on the cellular context.
Cell specific differences in KSHV biology are not without pre-
cedent. For example, whilemany cell types can be latently infected
in vitro, only a small subset of these can efficiently support full
lytic replication following treatment with chemical inducers
(Bechtel et al., 2003). Additionally, we and others have reported
modifications in cellular morphology upon latent KSHV infection
that occur only within the context of human primary endothelium
(Ciufo et al., 2001;Grossmann et al., 2006;Grundhoff andGanem,
2004; Pan et al., 2004; Tang et al., 2003); differences in KSHV
gene expression upon de novo infection and in stable latency have
also been reported to differ between cell type (Krishnan et al.,
2004; Rivas et al., 2001). Given these differences, which indicate
intricate and complex interactions of the KSHV genome with the
machinery of host gene expression, it is perhaps not surprising that
the relationship of lytic induction to NFκB activation is not
invariant in different cellular environments.
Finally, despite the earlier finding (Brown et al., 2003) that
p65-overexpression can impair reporter genes driven by KSHV
lytic promoters (outside of the context of viral infection), we find
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in endothelial, epithelial and fibroblast cell lines upon lytic
infection. Increased NFκB activity has also been observed in
PEL cell lines during lytic reactivation (Sgarbanti et al., 2004),
though those studies were complicated by the use of TPA as an
inducer (and the fact that isogenic KSHV-negative PEL cells are
not available as controls). Therefore, NFκB activation and lytic
gene expression cannot be strictly incompatible under all
circumstances. Whatever inhibitory influence p65 activation
may have on lytic promoters, it clearly can be at least partially
bypassed or overcome during full lytic infection. (That this
bypass is not complete is indicated by our recent observation that
when TPA is used to induce lytic reactivation in infected
HUVECs, titers of released virions are 2–3-fold higher in
the presence of IκB-SR expression; C.G., unpublished data.)
Exactly how this bypass is accomplished will require further
investigation.
Materials and methods
Cells and KSHV infection
Human umbilical vein endothelial cells (HUVECs) were
purchased from Clonetics and cultured in EGM-2 media
supplemented with the endothelial supplement pack (Clonetics).
Human foreskin fibroblasts (HFFs) were purchased from ATCC
and cultured in DMEM supplemented with 10% fetal bovine
serum, penicillin, streptomycin and L-glutamine. BCBL-1 cells
were carried in RPMI 1640 supplemented with 10% fetal bovine
serum, penicillin, streptomycin, glutamine and β-mercaptoetha-
nol. KSHV was concentrated from supernatants of induced
BCBL-1 cells as previously described (Bechtel et al., 2003;
Lagunoff et al., 2002). KSHV infections were done in media
containing 2 μg/ml polybrene and incubated with cells for 6 h,
after which cells were rinsed and media was added back. In the
case of lytic infection, Adeno-RTA (1×109 particles/ml) was
incubated in media plus 0.5 μg/ml polylysine (Sigma) for 2 h
before being applied to cells after the removal of the KSHV
containing media.
Retrovirus production and infection
Retroviruses were produced using the amphotropic Phoenix
packaging cell line transfected with the Moloney Murine
Leukemia Virus based vector pMXpie (a kind gift from Lewis
Lanier). Phoenix cells were transfected using FuGENE 6
(Roche) according to the manufacturer's specifications. 36 h
after transfection supernatants were collected and concentrated
at 5000 rpm for 16 h. Concentrated retroviruses were
resuspended in EGM-2 media with 6 μg/ml polybrene and
filtered through a 0.2 μm filter. Concentrated retrovirus was
diluted in EGM-2 media with 6 μg/ml polybrene and applied to
cells. These cultures were spun at 2000 rpm for 1.5 h after which
virus-containing media was removed and regular culture media
was added back. In cases where selection was employed, media
containing the selective agent was added to cells at the stated
concentration 24 h after transduction.Immunofluorescence and Western blotting
Immunofluorescence assays were performed as previously
described using anti-ORF59 (ABI) and an anti-mouse rhodamine
(SantaCruzBiotechnology) secondary antibodywas used at 1:300.
Lysates for Western blots were obtained by rinsing cells
twice with ice cold PBS, scraping adherent cells from the plate,
spinning cells at 1000 rpm for 5 min and resuspending pellets in
2–3× the pellet volume of RIPA lysis buffer. Lysates were
quantified using Biorad Protein Assay. 20 μg of protein were
run on 4–15% Tris–HCl gels and protein was transferred to
PVDF at 100 mV for 1 h at 4 °C. Blots were blocked for 1 h at
room temperature in 5%milk in TBS plus 0.1% Tween. Primary
antibodies were incubated overnight at 4 °C at 1:1000 anti-
PARP (Cell Signaling Technology), 1:5000 anti-β-actin
(A1978, Sigma); secondary antibodies, anti-mouse-HRP and
anti-rabbit-HRP (Santa Cruz) were incubated at 1:5000 for 1 h
at room temperature. Signal was detected using ECL Detection
Reagent (Amersham).
Bay 11-7082 treatment of BCBL-1 cells
Bay 11-7082 was purchased from Calbiochem, diluted in
DMSO and used at the concentrations stated. For reactivation
assays, BCBL-1 cells were resuspended in media containing Bay
11-7082, incubated for 30 min, then spun down and resuspended
in fresh media. RNA and protein lysates were harvested at 48 h
post Bay 11-7082 treatment.
KSHV virion DNA isolation
Media was removed from virus-producing cells, filtered
through a 0.45 μM filter and stored at 4 °C. 20 μ/ml DNase was
added to filtered supernatants and incubated at 37 °C for 1 h.
Supernatants were then chilled on ice and spun at 15,000 rpm for
2 h at 4 °C. Media was then removed and pelleted virus was
resuspended in 600 μl lysis buffer (20 mM Tris–HCl at pH 8,
10mMEDTA, 100mMNaCl, 0.5% SDS) and incubated at room
temperature for 10 min. 0.7 mg/ml Proteinase K and linearized
plasmid encoding an unrelated malaria gene were diluted in
100 μl lysis buffer and added to the 600 μl resuspended virions.
The 700 μl total volume was incubated at 55 °C for 2 h; this was
then extracted once with 700 μl phenol/chloroform/isoamyl.
600μl of the aqueous phase was removed and to it was added 3 μl
glycogen, 100μl 3M sodium acetate and 700μl isopropanol; this
was then spun at 15,000 rpm for 15 min at 4 °C. The resulting
pellet was rinsed once with 70% ethanol, spun and air dried
before being resuspended in 85 μl of water. 2 μl of this was used
in the subsequent Taqman and Sybergreen assays for PAN
promoter and spiked-in malaria gene as a normalizing factor.
Taqman and Sybergreen real time PCR assays
For all Taqman assays, 200 ng of RNAwas reverse transcribed
using SuperScript III and oligo d(T) primer (Invitrogen) ac-
cording to themanufacturer's instructions. 2 μl of this reactionwas
used in all subsequent real time PCR Taqman assays. Primer and
101C. Grossmann, D. Ganem / Virology 375 (2008) 94–102probe sequences used for lytic gene expression ORF50 are pre-
viously described (Bechtel et al., 2005). Other primers used were
ORF 57 forward: TGGACATTATGAAGGGCATCC, reverse:
CGGGTTCGGACAATTGCT; gB forward: TCGCCGCAC-
CAATACCATA, reverse: CCTGCGATCTACGTCGGG; PAN
promoter forward: GCCAGCTTGAGTCAGTTTAGCA, reverse:
CGAGCACAAAATCCATAGGTG; and Malaria DNA forward:
AGGACCCGATCAACAACAT, reverse: AAGCTGAACAA-
GAACGCGAT. Taqman reactions (all but malaria DNA) were
performed using Taqman Universal Master Mix (Applied
Biosystems) and Sybergreen reactions (malaria DNA) were
performed using SybergreenER mastermix (Invitrogen) as per
the manufacturer's specifications.
Nfκb Emsa
Nuclear enriched lysates were made from cells by incubation
in hypotonic buffer (20 mM HEPES at pH 7.8, 5 mM KCl,
1.5 mM MgCl2, 1 mM DTT and protease inhibitors), followed
by pelleting and disruption of nuclei by incubation in high salt
buffer (0.4 M KCl, 50 mM HEPES at pH 7.9, 0.1% NP40,
0.5 μM EDTA, 10% glycerol and protease inhibitors). 5 μg of
lysate was incubated with 32P-labled oligonucleotide encoding
the NFκB consensus sequence (Santa Cruz Biotechnology), and
dI:dC DNA (Sigma) in binding buffer (20 μM HEPES at pH
7.9, 50 mM KCl, 10% glycerol, 1 mM EDTA, 1 mM MgCl2,
1 mM DTT). Reactions were incubated at room temperature for
30 min without the labled probe and an additional 30 min after
addition of the probe. Complexes were resolved in a 1× TBE,
4% acrylamide gel.
NFκB-luciferase assay
293Tcells were transfected using Fugene 6 (Roche) as per the
manufacturer's specifications with increasing amounts for the
following constructs: pNFκB-luc (BDBiosciences), pCDNA3.1-
RTA, pCD8 (Mylteni Biotech). 36 h post transfection cells were
passed over anti-CD8 MACS columns (Mylteni Biotech) to
enrich for cells expressing CD8 and RTA. The separated cells
were plated and allowed to recover overnight. The next morning
cells were either mock-infected or infected with KSHV in
triplicate. 48 h post infection luciferase levels were assayed as per
the manufacturer's specifications (Promega).
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